Producing Therapies for the Brain: Manufacturing and Formulation Challenges for CNS Biologics

Key Takeaways

• The BBB fundamentally shapes CNS biologic development. Because most biologic therapeutics cannot readily cross the BBB, developers must design therapies, delivery strategies, and manufacturing processes specifically to address this biological constraint.

• Viral vector production remains a central manufacturing challenge for CNS gene therapies. Platforms like AAV require complex upstream and downstream processes, and scaling production to meet dosing requirements for CNS delivery continues to present major technical hurdles.

• Analytical characterization is critical for ensuring gene therapy product quality. Capsid heterogeneity, including full, empty, and partially filled viral particles, requires advanced analytical methods to support quality control, regulatory compliance, and reliable process scale-up.

• Engineering protein biologics for brain delivery introduces additional manufacturing considerations. Strategies like receptor-mediated transport and bispecific antibody design can improve brain penetration but also affect protein structure, expression systems, purification processes, and analytical characterization.

• CNS delivery strategies tightly link formulation, device design, and manufacturing controls. Routes such as intrathecal and intracerebroventricular administration impose constraints on formulation stability, dosing parameters, and infusion systems, reinforcing the need for integrated CMC development strategies.

Therapeutic development for diseases of the central nervous system (CNS) has long faced an obstacle that distinguishes it from most other areas of medicine: the blood–brain barrier (BBB). This specialized physiological interface regulates the exchange of molecules between the bloodstream and the brain, maintaining neural homeostasis while protecting the CNS from toxins and pathogens circulating in the blood. The barrier’s tightly connected endothelial cells and selective transport mechanisms allow essential nutrients and signaling molecules to pass while restricting many other substances, including a large proportion of potential therapeutics.¹

For biologic drugs, this constraint is particularly significant. Large molecule therapeutics, including recombinant proteins, monoclonal antibodies, and gene-therapy vectors, generally do not cross the BBB efficiently under normal physiological conditions. When administered systemically, these therapies often fail to reach therapeutically meaningful concentrations in brain tissue. As a result, the central challenge in developing biologic treatments for neurological disease is not only identifying effective therapeutic targets but also determining how those therapies can be delivered to the brain in sufficient amounts to achieve clinical benefit.²

Developers pursuing biologic modalities for CNS diseases have therefore been forced to design therapies and delivery strategies around this barrier. One category of approaches attempts to exploit endogenous transport mechanisms within the BBB. Engineered antibodies and fusion proteins, for example, can be designed to interact with receptors that mediate transcytosis across the endothelial cells of the barrier, enabling biologics to enter the brain by leveraging transport pathways normally used for physiological molecules.³ Other strategies avoid the BBB altogether by delivering therapeutics directly into the cerebrospinal fluid (CSF) or brain tissue through routes such as intrathecal or intracerebroventricular administration. These approaches allow biologic modalities that would otherwise be excluded by the BBB to reach CNS targets more directly.⁴

While these strategies address the problem of delivery, they introduce additional layers of complexity that extend into chemistry, manufacturing, and controls (CMC) development. Engineering biologics to engage BBB transport pathways can alter molecular structure and production requirements. Delivery routes that bypass the barrier may require higher doses, specialized formulations compatible with CSF administration, or delivery devices designed for infusion into the CNS. Each of these factors can influence how therapeutics must be produced, purified, formulated, and characterized.

The BBB does not only shape the pharmacology of CNS therapeutics; it also influences the manufacturing strategies that support them. The need to overcome or circumvent this biological barrier has driven the development of specialized approaches for producing viral vectors used in gene therapies, engineering antibodies capable of brain transport, and formulating protein therapeutics intended for CNS delivery. As biologic modalities increasingly move to the forefront of neurological drug development, understanding how these biological constraints translate into manufacturing and CMC challenges is becoming an essential component of successful program design.

Among the biologic modalities being explored for neurological diseases, viral vector–based gene therapies have emerged as one of the most prominent. In particular, recombinant adeno-associated virus (AAV) vectors have become a widely used platform for delivering therapeutic genes in both experimental and clinical programs. Their popularity stems from a number of biological characteristics that make them well suited for gene delivery, including relatively low immunogenicity and the ability to transduce both dividing and non-dividing cells. These properties have made AAV an important tool in gene therapy more broadly and a particularly attractive platform for applications targeting the CNS.⁵

The expansion of AAV-based therapeutics has brought increasing attention to the manufacturing processes required to support these therapies. Unlike conventional small molecule drugs, viral vectors are complex biological products whose production involves multiple interconnected steps that must be carefully controlled to ensure product quality and consistency. A typical AAV manufacturing workflow spans upstream vector generation, downstream purification, and formulation and fill–finish operations that prepare the final product for clinical administration.⁶

Upstream manufacturing typically involves the production of AAV particles in cultured cells, most commonly through plasmid transfection systems. In this process, host cells are engineered to produce viral capsid proteins and package the therapeutic genetic payload into assembled vector particles. Once vector production is complete, downstream processing begins with the recovery of viral particles from the cell culture system, followed by purification steps designed to remove host cell proteins, nucleic acids, and other impurities. These purification steps may include chromatography, filtration, and other separation technologies that enrich the desired vector population while removing process-related contaminants. Finally, purified vectors are formulated in appropriate buffers and excipients before undergoing fill–finish operations that prepare the material for storage, transport, and administration.^6,7

Despite significant advances in process development, producing AAV vectors at large scale remains a major challenge. Viral particle yields can be relatively low, particularly when using production systems originally developed for research-scale applications. Manufacturing platforms based on adherent cell culture systems can present additional limitations when production volumes increase, requiring the development of alternative approaches to achieve larger manufacturing capacity. As demand for gene therapies continues to expand, the ability to generate sufficient quantities of high-quality vector material has become one of the defining challenges of the field.⁸

Beyond simple scale considerations, AAV manufacturing also involves a high degree of process complexity. Each stage of production — from cell culture and vector assembly to purification and formulation — introduces variables that can affect the final product. Multiple unit operations must be coordinated to maintain vector integrity while removing impurities and ensuring consistency across production batches. This complexity places significant demands on process development, analytical characterization, and quality control strategies throughout the manufacturing life cycle.⁷

When gene therapies are designed to target the CNS, these manufacturing challenges become more pronounced because delivery to neural tissues remains constrained by the BBB. In some programs, this constraint may translate into higher vector doses or specialized delivery approaches intended to improve distribution within neural tissues. These considerations link the biological challenges of CNS drug delivery directly to manufacturing requirements, reinforcing the need for scalable, well-controlled production platforms capable of supplying sufficient quantities of vector material for clinical use.

Ensuring the quality and consistency of viral vector products is a central requirement for the successful development and manufacture of gene therapies. For AAV-based therapeutics, one of the most persistent challenges arises from the inherent heterogeneity of vector preparations. During vector production, the assembly and packaging process does not yield a uniform population of particles. Instead, manufacturing batches typically contain a mixture of capsid types that differ in whether and how completely they contain the intended genetic payload.

Three primary capsid species are commonly observed in AAV preparations: full capsids containing the therapeutic genome, empty capsids that lack packaged DNA, and intermediate capsids that contain partial or incomplete genetic material. From a therapeutic perspective, only the full capsids contribute directly to gene delivery and clinical activity. Empty and intermediate capsids represent product-related impurities that can affect product potency, dosing strategies, and safety considerations. As a result, these capsid populations must be carefully identified, quantified, and controlled in clinical-grade vector preparations.⁷

Managing capsid heterogeneity presents a significant challenge for downstream purification. Although full and empty capsids differ in their internal composition, their external protein structures are highly similar. Because most purification technologies rely on physicochemical properties (e.g., size, charge, or hydrophobicity), these similarities can make it difficult to separate the various capsid populations efficiently. Downstream purification steps designed to remove process-related contaminants may therefore co-purify empty or partially filled capsids alongside the desired therapeutic particles. Achieving a sufficiently enriched population of full capsids requires careful optimization of purification strategies and analytical monitoring throughout process development.⁷

These challenges have increased the importance of advanced analytical characterization tools in AAV manufacturing. Reliable measurement of capsid composition is necessary not only to confirm product quality but also to support process development and scale-up activities. Analytical methods must be capable of distinguishing among different capsid species and quantifying their relative proportions in production batches. Such measurements provide insight into the efficiency of vector packaging during upstream production and the effectiveness of purification strategies during downstream processing. As AAV manufacturing processes are scaled for clinical and commercial supply, these analytical capabilities play an increasingly important role in defining critical quality attributes and guiding process optimization.⁷

The need for rigorous analytical characterization is closely tied to regulatory expectations for gene therapy products. Regulatory authorities require developers to provide comprehensive CMC documentation demonstrating that viral vector products meet defined standards for identity, purity, potency, and safety. Manufacturing processes must therefore be designed and validated to consistently produce vectors that meet these specifications across production batches. Analytical methods that can reliably measure vector attributes and detect impurities are essential to establishing product consistency and supporting regulatory review.⁶

For CNS-targeted gene therapies, these requirements take on additional significance. Because the delivery of therapeutic genes to neural tissues often depends on precise dosing and carefully controlled administration strategies, variability in vector quality can have important clinical implications. Robust quality control and analytical characterization frameworks are therefore essential components of manufacturing strategies for viral vector–based CNS therapeutics.

While viral vectors dominate many gene therapy strategies for neurological diseases, protein biologics remain an important and expanding class of therapeutics being investigated for CNS disorders. Monoclonal antibodies, enzyme replacement therapies, and other engineered proteins are being developed to target pathogenic pathways associated with neurodegenerative diseases, lysosomal storage disorders, and other neurological conditions. These biologics offer the ability to selectively modulate specific molecular targets within the brain, but their therapeutic potential is closely tied to the ability to deliver enough of the protein across or around the BBB.

Conventional protein therapeutics administered intravenously typically exhibit extremely limited penetration into brain tissue because of the restrictive properties of the BBB. As a result, researchers have increasingly explored molecular engineering approaches that allow biologics to exploit endogenous transport pathways within the barrier. One widely studied strategy involves designing therapeutic proteins that interact with receptors expressed on the endothelial cells that form the BBB. These receptors participate in receptor-mediated transcytosis, a physiological transport mechanism that moves specific macromolecules from the bloodstream into the brain. By linking therapeutic proteins or antibodies to ligands or antibody fragments that bind these receptors, developers can create engineered biologics capable of traversing the BBB through natural cellular transport processes.³

Several variations of this concept have emerged in CNS drug development. Some approaches involve antibody–drug conjugates (ADCs) or fusion proteins in which a therapeutic payload is linked to a targeting domain that binds a BBB transport receptor. Other strategies use bispecific antibodies that simultaneously bind a receptor involved in BBB transport and a disease-related target within the CNS. These designs attempt to maintain therapeutic activity while improving brain penetration, enabling biologics to reach targets that would otherwise remain inaccessible.⁹

While these molecular engineering strategies focus primarily on improving CNS delivery, they also introduce new considerations for manufacturing and CMC development. Engineering proteins to incorporate receptor-binding domains, fusion constructs, or bispecific architectures can alter molecular size, structure, and stability, which in turn influences production processes. Expression systems must be optimized to produce the modified proteins efficiently while maintaining correct folding and post-translational modifications. Changes in molecular architecture may also affect purification strategies, as engineered proteins can exhibit different physicochemical properties than conventional monoclonal antibodies.

Analytical characterization becomes correspondingly more complex as protein designs evolve. Developers must confirm not only the identity and purity of the therapeutic protein but also the structural integrity of engineered domains and the functional interactions required for BBB transport. Assays used to evaluate binding affinity, receptor engagement, and biological activity therefore become critical components of product characterization. As CNS-targeted biologics continue to incorporate increasingly sophisticated molecular designs, manufacturing and analytical strategies must adapt to ensure that these engineered proteins can be produced reproducibly and characterized with sufficient rigor to support clinical development.

Formulation development plays a critical role in the successful deployment of protein biologics for CNS diseases. Unlike small molecule drugs, therapeutic proteins are structurally complex and can be sensitive to a variety of physical and chemical stressors encountered during manufacturing, storage, and administration. As a result, maintaining the stability of protein therapeutics throughout the product lifecycle is a central concern in formulation design.

Protein biologics can undergo several forms of degradation that compromise product quality and therapeutic performance. Physical instability often manifests as aggregation, in which protein molecules associate into higher-order structures that can reduce potency and increase the risk of immunogenic responses. Chemical degradation pathways can also occur, including oxidation, hydrolysis, and other structural modifications that alter the molecular integrity of the therapeutic protein. Environmental factors such as temperature fluctuations, exposure to interfaces, agitation, and interactions with formulation components can further influence these degradation pathways, making stability control a multifaceted challenge in biologic product development.¹⁰

These issues become particularly significant when protein therapeutics must be formulated at high concentrations. Many biologic drugs are delivered through administration routes that restrict the volume that can be safely injected or infused, including subcutaneous and ocular delivery. To achieve the required therapeutic dose within these volume constraints, formulations often contain highly concentrated protein solutions. Increasing protein concentration, however, can amplify intermolecular interactions that promote aggregation and other forms of instability. Higher protein concentrations may also increase solution viscosity, complicating both manufacturing processes and administration through injection devices.¹¹

For CNS-targeted protein therapeutics, formulation challenges intersect with the specialized delivery strategies required to reach neural tissues. Because the BBB limits the effectiveness of conventional systemic administration for many biologics, alternative delivery routes, such as intrathecal or intracerebroventricular administration (vide infra), are frequently explored. These approaches introduce additional formulation considerations related to compatibility with CSF environments and the physical constraints of CNS infusion systems.

Parameters, such as drug concentration, excipient composition, and injection volume, can influence the distribution of therapeutics within cerebrospinal fluid and their ability to reach target tissues in the brain or spinal cord. Formulations must therefore be designed not only to maintain protein stability but also to support predictable distribution and tolerability within the CNS compartment. In addition, the viscosity and physical properties of the formulation can influence infusion dynamics and device performance during administration.

Because many biologic therapeutics cannot cross the BBB efficiently after systemic administration, CNS drug development programs frequently rely on alternative delivery strategies that introduce therapeutics directly into the central nervous system. Among the most widely studied approaches are intrathecal administration, in which therapeutics are delivered into the CSF through the spinal canal, and intracerebroventricular administration, which delivers drugs directly into the brain’s ventricular system. These approaches allow biologic modalities, including antibodies, enzymes, and gene therapies, to bypass the vascular barrier and access neural tissues that would otherwise remain difficult to reach through conventional intravenous dosing.⁴

Although these routes offer a means of circumventing the BBB, they also introduce new complexities for CMC development. Unlike systemic circulation, the CSF compartment is characterized by distinct physiological properties and dynamic fluid circulation patterns that influence how therapeutics distribute within the CNS. The movement of CSF through the ventricular system and around the brain and spinal cord affects how injected drugs spread from the site of administration and reach target tissues. As a result, factors that might play a relatively minor role in systemic dosing can become critical determinants of therapeutic distribution within the CNS environment.

Several parameters can influence the behavior of biologics delivered through CSF-based routes. Infusion rate and duration, for example, can affect how a therapeutic disperses within the CSF and how effectively it reaches specific regions of the brain or spinal cord. Similarly, the concentration of the drug within the administered formulation can influence both local distribution and the ability to achieve therapeutic levels at distant target sites. Formulation composition can also play a role, as excipients and buffer systems must remain compatible with the delicate physiological environment of the CNS while maintaining the stability of the therapeutic molecule.¹²

These considerations link delivery strategy directly to formulation design and manufacturing controls. Formulations intended for CNS administration must maintain stability while also supporting predictable dispersion within the CSF compartment. At the same time, injection volumes must remain within limits that avoid excessive increases in intracranial pressure or other adverse physiological effects. Achieving this balance often requires careful optimization of both drug concentration and dosing parameters.¹³

The devices used to administer CNS-targeted biologics introduce another layer of complexity. Intrathecal and intracerebroventricular delivery frequently rely on specialized infusion systems, including catheters, implanted reservoirs, or pump-driven delivery platforms designed for precise administration into CSF spaces. These devices must operate reliably with the selected formulation, requiring compatibility between the physical properties of the drug product and the materials used in the delivery system.

As a result, the development of CNS biologics often requires close coordination between formulation scientists, device engineers, and clinical teams. Delivery route, infusion parameters, formulation design, and manufacturing controls must be considered together to ensure that the therapeutic can be produced consistently and administered safely. In this way, CNS delivery strategies do more than overcome the BBB; they reshape the CMC landscape by linking product formulation, dosing strategy, and device integration into a unified development challenge.

For biologic therapies targeting the central nervous system, manufacturing strategy cannot be considered independently from delivery strategy. The biological barriers that limit drug entry into the brain, particularly the BBB, shape not only how therapies must be administered but also how they must be produced, formulated, and characterized. As a result, decisions about vector design, protein engineering, formulation composition, and dosing approaches are closely linked to the practical realities of manufacturing and CMC development.

One important interdependency arises between vector dose and manufacturing scale in gene therapy programs. Viral vector–based therapies, particularly those using AAV, must be produced in sufficient quantities to support the dosing strategies required for CNS delivery. Biological barriers that restrict distribution to neural tissues can influence how much vector must be administered to achieve therapeutic levels in the brain. These dosing considerations place pressure on manufacturing platforms to generate large quantities of high-quality vector material while maintaining consistency and regulatory compliance.^6,7

Formulation design also intersects directly with delivery strategy. The physical and chemical properties of a biologic formulation influence not only product stability but also how the therapeutic behaves during administration. For CNS-targeted biologics delivered into CSF, formulation properties such as concentration, viscosity, and excipient composition can affect both the safety of the injection and the distribution of the drug within the CNS environment. As a result, formulation development must consider the intended delivery route and dosing parameters, ensuring that the final product remains stable while supporting effective administration.¹²

Analytical characterization and regulatory expectations further reinforce the connection between manufacturing and delivery strategy. Gene therapy and other complex biologic modalities require detailed analytical methods to confirm product identity, purity, potency, and structural integrity. These analytical frameworks must be capable of monitoring the attributes that influence clinical performance, including factors related to vector composition, molecular structure, and functional activity. Establishing reliable analytical tools therefore becomes essential not only for product quality control but also for supporting the clinical strategies used to deliver therapeutics to the CNS.⁷

Because these elements are so tightly linked, CNS drug development programs often benefit from early integration of CMC planning with clinical and translational strategy. Process development teams, formulation scientists, analytical specialists, and clinical investigators must work together to ensure that therapeutic design, manufacturing capabilities, and delivery approaches evolve in a coordinated way. This level of cross-disciplinary collaboration can help identify potential bottlenecks early in development and improve the likelihood that promising CNS biologics can be translated into viable clinical therapies.

The rapid expansion of biologic modalities for neurological diseases has intensified efforts to improve the technologies that support their production and characterization. Advances in viral vector manufacturing, analytical methods, and molecular engineering are beginning to reshape how CNS-targeted biologics are developed and produced. While many challenges remain, progress in these areas has the potential to improve both the scalability and reliability of manufacturing platforms that support therapies for neurological disorders.

One area of ongoing development involves improvements in viral vector production technologies. As AAV-based gene therapies continue to advance through clinical development, increasing attention is being directed toward manufacturing systems capable of producing larger quantities of vector material with consistent quality. Innovations in cell culture platforms, vector production strategies, and purification technologies are being explored to address limitations in viral particle yield and scalability that have historically constrained AAV manufacturing. Efforts to refine upstream production systems and downstream purification workflows are expected to play an important role in enabling the broader clinical application of gene therapies targeting the CNS.^6,7

Advances in analytical characterization methods represent another important area of progress. As viral vectors and engineered biologics become more complex, analytical tools capable of resolving subtle differences in product composition are increasingly necessary. Improved analytical techniques for characterizing capsid populations, structural attributes, and functional activity can provide deeper insight into the critical quality attributes of gene therapy products. These capabilities support quality-by-design approaches to process development, enabling developers to better understand how manufacturing parameters influence product quality and therapeutic performance.⁷

At the same time, molecular engineering strategies aimed at enhancing brain delivery may influence future manufacturing requirements. Approaches that enable biologics to cross the BBB more efficiently, including receptor-mediated transport mechanisms and engineered antibody architectures, could reduce the need for high systemic doses or specialized administration routes. Improvements in the efficiency of CNS delivery may therefore have downstream implications for manufacturing scale, formulation design, and dosing strategies.^3,9

Collectively, these developments may expand the therapeutic possibilities for biologic approaches to neurological disease. Improved production platforms, more sophisticated analytical tools, and advances in delivery engineering could enable biologics to address a broader range of conditions affecting the CNS. These include neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease, genetic neurological disorders that require targeted gene delivery, and other conditions in which protein or gene-based therapeutics offer new treatment possibilities. As manufacturing technologies continue to evolve alongside advances in CNS biology, the capacity to reliably produce complex biologic therapies will remain a central factor in translating scientific discoveries into clinically viable treatments.

One of the defining lessons emerging from CNS biologic development is that manufacturing can no longer be treated as a downstream activity that follows therapeutic discovery. In programs targeting the brain, the biological constraints imposed by the BBB and the delivery strategies required to overcome it influence therapeutic design from the earliest stages of development. As a result, decisions about vector engineering, protein architecture, formulation strategy, and manufacturing platforms are tightly interconnected long before clinical production begins.

This reality is forcing a shift in how CNS biologic programs are designed and executed. Rather than progressing through the traditional sequence of discovery, delivery optimization, and manufacturing scale-up, successful programs increasingly integrate these elements from the outset. Vector dose requirements influence manufacturing platform selection; delivery route constraints shape formulation development; and analytical strategies must be capable of characterizing complex biologic products as processes scale. In CNS programs, these considerations are not secondary development challenges but core determinants of whether a therapy can ultimately be produced and delivered successfully.

For developers pursuing treatments for neurodegenerative disease, genetic neurological disorders, and other conditions affecting the central nervous system, this shift has important implications. Progress will depend not only on advances in neuroscience or molecular engineering but also on the ability of development teams to coordinate expertise across biologic design, process engineering, formulation science, and clinical delivery technologies. Organizations that build these integrated capabilities early in development are likely to be best positioned to translate emerging biologic modalities into viable CNS therapies.

As the field continues to evolve, the next generation of breakthroughs in neurological medicine may depend as much on advances in manufacturing and delivery technologies as on discoveries in biology itself.

1. Wu, Di, et al. “The blood–brain barrier: Structure, regulation and drug delivery.” Signal Transduction and Targeted Therapy. 8: 217 (2023).

2. Pardridge, William M. “Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain.” Front. Aging Neurosci. 11: 373 (2020).

3. Zhao, Peng, Ningyan Zhang, and Zhiqiang An. “Engineering antibody and protein therapeutics to cross the blood–brain barrier.” Antibody Therapeutics. 5:311–331 (2022).

4. Jiao, Yimai, et al. “Drug Delivery Across the Blood–Brain Barrier: A New Strategy for the Treatment of Neurological Diseases.” Pharmaceutics. 16: 1611 (2024).

5. Coughlin, Gerard M, et al. “Spatial genomics of AAV vectors reveals mechanism of transcriptional crosstalk that enables targeted delivery of large genetic cargo.” Nat. Biotechnol. 44: 133–145 (2026).

6. Kowshik, N Charan SS, and Pushpendra Singh. “Advancing AAV vector manufacturing: challenges, innovations, and future directions for gene therapy.” Front. Mol. Med. Sec. Gene and Virotherapy. 2 Dec. 2025.

7. Srivastava, Arvind, et al. “Manufacturing Challenges and Rational Formulation Development for AAV Viral Vectors.” J. Pharm. Sci. 110: 2609–2624 (2021).

8. Moldavskii, Daniil, et al. “AAV-Based Gene Therapy: Opportunities, Risks, and Scale-Up Strategies.” Int. J. Mol. Sci. 26: 8282 (2025).

9. Boado, Ruben J. “IgG Fusion Proteins for Brain Delivery of Biologics via Blood–Brain Barrier Receptor-Mediated Transport.” Pharmaceutics. 14: 1476 (2022).

10. Le Basle, Yoann, et al. “Physicochemical Stability of Monoclonal Antibodies: A Review.” Journal of Pharmaceutical Sciences. 109: 169–190 (2020).

11. Zarzar, Jonathan, et al. “High concentration formulation developability approaches and considerations." mAbs. 15: 2211185 (2023).

12. Kouzehgarani, Ghazal Naseri, et al. “Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues.” Advanced Drug Delivery Reviews. 173: 20–59 (2021).

13. Schreiner, Thomas Gabriel, et al. “Intrathecal Therapies for Neurodegenerative Diseases: A Review of Current Approaches and the Urgent Need for Advanced Delivery Systems.” Biomedicines. 13: 2167 (2025).